EU Safety Gate (RAPEX) · France · 2025-08-29 · Serious risk
🌐Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Reported risk: Le produit contient de l'hydroxyde de sodium qui est corrosif pour la peau, mais il ne comporte pas les pictogrammes de danger, les avertissements, les mentions de prudence appropriés ni une fermeture résistante aux enfants. Les utilisateurs n'ont aucune information sur l'utilisation sûre et les dangers du produit, et pourraient accidentellement subir une corrosion cutanée grave ou des lésions oculaires graves. Le produit n'est pas conforme au règlement sur la classification, l'étiquetage et l'emballage (CLP).
Action taken by the authority
Type of economic operator taking notified measure
Other
Category of measure
Warning consumers of the risks
Date of entry into force
05/08/2025
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.
Product Name (original English): Pipeline dredging agent
Risk Description (original English): The product contains sodium hydroxide that is corrosive to the skin, but lacks the appropriate hazard pictograms, warnings, precautionary statements and a child-resistant fastening. Users have no information on the safe use and the dangers of the product, and could accidentally suffer from severe skin corrosion or serious damage to the eyes.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.